EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

A Nationwide Study on HER2-Low Breast Cancer in South Korea: Its Incidence of 2022 Real World Data and the Importance of Immunohistochemical Staining Protocols

Min Chong Kim, Eun Yoon Cho, So Yeon Park, Hee Jin Lee, Ji Shin Lee, Jee Yeon Kim, Ho-Chang Lee, Jin Ye Yoo, Hee Sung Kim, Bomi Kim, Wan Seop Kim, Nari Shin und 17 weitere

Cancer Research and Treatment · 2024

DOI: 10.4143/crt.2024.092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Min Chong Kim und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Yeungnam University College of Medicine, Daegu, Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Immunohistochemistry, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Korean Society of Pathologists.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Notable effectiveness of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)–low advanced breast cancer (BC) has focused pathologists’ attention. We studied the incidence and clinicopathologic characteristics of HER2-low BC, and the effects of immunohistochemistry (IHC) associated factors on HER2 IHC results.Materials and Methods The Breast Pathology Study Group of the Korean Society of Pathologists conducted a nationwide study using real-world data on HER2 status generated between January 2022 and December 2022. Information on HER2 IHC protocols at each participating institution was also collected.

Results

Total 11,416 patients from 25 institutions included in this study. Of these patients, 40.7% (range, 6.0% to 76.3%) were classified as HER2-zero, 41.7% (range, 10.5% to 69.1%) as HER2-low, and 17.5% (range, 6.7% to 34.0%) as HER2-positive. HER2-low tumors were associated with positive estrogen receptor and progesterone receptor statuses (p < 0.001 and p < 0.001, respectively). Antigen retrieval times (≥ 36 minutes vs. < 36 minutes) and antibody incubation times (≥ 12 minutes vs. < 12 minutes) affected on the frequency of HER2 IHC 1+ BC at institutions using the PATHWAY HER2 (4B5) IHC assay and BenchMark XT or Ultra staining instruments. Furthermore, discordant results between core needle biopsy and subsequent resection specimen HER2 statuses were observed in 24.1% (787/3,259) of the patients.

Conclusion

The overall incidence of HER2-low BC in South Korea concurs with those reported in previously published studies. Significant inter-institutional differences in HER2 IHC protocols were observed, and it may have impact on HER2-low status. Thus, we recommend standardizing HER2 IHC conditions to ensure precise patient selection for targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesImmunohistochemistryBiomarkers, TumorHumansFemaleRepublic of KoreaIncidenceMiddle AgedAdultAgedAged, 80 and over

Stichwörter der Autor:innen

Breast neoplasmsHER2-lowHER2-testingImmunohistochemistry

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Yeungnam University College of Medicine, Daegu, Korea.
  • Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Pathology, Chonnam National University Medical School, Gwangju, Korea.
  • Department of Pathology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.

Förderung

  • Korean Society of Pathologists

Zitieren

APA

Kim, M. C., Cho, E. Y., Park, S. Y., Lee, H. J., Lee, J. S., Kim, J. Y., Lee, H. C., Yoo, J. Y., Kim, H. S., Kim, B., Kim, W. S., Shin, N., Maeng, Y. H., Kim, H. S., Kwon, S. Y., Kim, C., Jun, S. Y., Kwon, G. Y., Choi, H. J., …, & Bae, Y. K. (2024). A Nationwide Study on HER2-Low Breast Cancer in South Korea: Its Incidence of 2022 Real World Data and the Importance of Immunohistochemical Staining Protocols. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.092

Vancouver

Kim MC, Cho EY, Park SY, Lee HJ, Lee JS, Kim JY, et al. A Nationwide Study on HER2-Low Breast Cancer in South Korea: Its Incidence of 2022 Real World Data and the Importance of Immunohistochemical Staining Protocols. Cancer Research and Treatment. 2024. doi:10.4143/crt.2024.092

BibTeX
@article{Kim2024,
  author = {Kim, Min Chong and Cho, Eun Yoon and Park, So Yeon and Lee, Hee Jin and Lee, Ji Shin and Kim, Jee Yeon and Lee, Ho-Chang and Yoo, Jin Ye and Kim, Hee Sung and Kim, Bomi and Kim, Wan Seop and Shin, Nari and Maeng, Young Hee and Kim, Hun Soo and Kwon, Sun Young and Kim, Chungyeul and Jun, Sun-Young and Kwon, Gui Young and Choi, Hye Jeong and Lee, So Mang and Choi, Ji Eun and An, Ae Ri and Choi, Hyun Joo and Kim, EunKyung and Kim, Ahrong and Kim, Ji-Young and Shim, Jeong Yun and Gong, Gyungyub and Bae, Young Kyung},
  title = {A Nationwide Study on HER2-Low Breast Cancer in South Korea: Its Incidence of 2022 Real World Data and the Importance of Immunohistochemical Staining Protocols},
  journal = {Cancer Research and Treatment},
  year = {2024},
  doi = {10.4143/crt.2024.092}
}
Kostenlos starten →